tucidinostat
Selected indexed studies
- Tucidinostat plus pediatric-inspired chemotherapy for newly diagnosed adult ETP-ALL/LBL: a single-arm, phase 2 trial. (J Hematol Oncol, 2024) [PMID:39468701]
- Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment. (Front Pharmacol, 2022) [PMID:36120308]
- Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results. (Haematologica, 2023) [PMID:36200417]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Tucidinostat plus pediatric-inspired chemotherapy for newly diagnosed adult ETP-ALL/LBL: a single-arm, phase 2 trial. (2024) pubmed
- Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment. (2022) pubmed
- Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results. (2023) pubmed
- Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer: a long-term safety and overall survival update from the randomised, double-blind, placebo-controlled, phase 3 trial. (2023) pubmed
- Effects of tucidinostat in adult T-cell leukemia/lymphoma in clinical practice. (2025) pubmed
- Abemaciclib-based therapy versus tucidinostat-based therapy in patients with HR(+)HER2(-) metastatic breast cancer after palbociclib progression: insights and challenges from a comparative cohort study in China. (2023) pubmed
- Tucidinostat restores CCR4 expression in adult T-cell leukemia/lymphoma. (2024) pubmed
- Recent histone deacetylase inhibitors in cancer therapy. (2023) pubmed
- Long-term efficacy and safety of tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: final analysis of phase IIb results. (2024) pubmed
- Tucidinostat Plus Exemestane as a Neoadjuvant in Early-Stage, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. (2024) pubmed